Durable reductions in TG, remnant cholesterol and ApoB levels with the hepatic ANGPTL3-silencing agent, zodasiran, in patients (n=204) with mixed hyperlipidaemia, including those with elevated TG, were reported at the congress and published simultaneously in the New England Journal of Medicine.1,2
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
